Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to study an experimental drug called PTP-01 that is
being used as an imaging agent to diagnosis pancreatic cancer. Currently, pancreatic cancer
is diagnosed using CT or MRI scans which miss small pancreatic cancers, particularly early
stage disease. Researchers at the University of Virginia have identified a biomarker for
pancreatic cancer called plectin, which is very specific for pancreatic cancer and not other,
non-cancerous conditions involving the pancreas. These researchers have also developed
PTP-01, an experimental drug that may be used with SPECT imaging to detect pancreatic cancer
cells in humans.